All holdings
Standard Biotools LAB
Source: the SEC Form 13F filings of the managers we follow, latest for Q2 2026. How we use them
Managers holding
1
In their latest 13F (Q2 2026)
See who
Value held
$48.3m
Combined value at quarter end
Last quarter
0 bought
0 sold or trimmed
Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance
Who holds it Over time About the company
Managers holding it, by quarter 0 Q4 ’23
1 Q1 ’24
1 Q2 ’24
1 Q3 ’24
1 Q4 ’24
1 Q1 ’25
1 Q2 ’25
1 Q3 ’25
1 Q4 ’25
1 Q1 ’26
1 Q2 ’26
0 Q3 ’26
Q4 ’23: 0; Q1 ’24: 1; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0 Counts the managers on this site whose 13F for that quarter includes Standard Biotools.
Who holds it Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.
Managers holding Standard Biotools Manager Portfolio▼ Value Change Held for Viking Global Investors 0.1%$48.3m $48.3m 10 qtrs
Download the holders: CSV · JSON · Markdown
About the company Sector Health care · Pharmaceutical Preparations Incorporated in Delaware Financial year ends 31 December Shares outstanding 393m at 3 Aug 2026 SEC filings Annual reports and other filings on EDGAR Revenue and profit $71.2m 2013
$116m 2014
$138m 2020
$131m 2021
$97.9m 2022
$106m 2023
$91.0m 2024
$85.3m 2025
2013: $71.2m; 2014: $116m; 2020: $138m; 2021: $131m; 2022: $97.9m; 2023: $106m; 2024: $91.0m; 2025: $85.3m Standard Biotools revenue and net income by year Year Revenue Net income 2025 $85.3m −$74.9m 2024 $91.0m −$139m 2023 $106m −$74.7m 2022 $97.9m −$190m 2021 $131m −$59.2m 2020 $138m −$53.0m 2014 $116m −$52.8m 2013 $71.2m −$16.5m
From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.